Discover Oncology (Jun 2022)

Apigenin impedes cell cycle progression at G2 phase in prostate cancer cells

  • Su Su Thae Hnit,
  • Mu Yao,
  • Chanlu Xie,
  • Ling Bi,
  • Matthew Wong,
  • Tao Liu,
  • Paul De Souza,
  • Zhong Li,
  • Qihan Dong

DOI
https://doi.org/10.1007/s12672-022-00505-1
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 12

Abstract

Read online

Abstract As a natural flavone, apigenin is abundantly present in vegetables, fruits, oregano, tea, chamomile, wheat sprout and is regarded as a major component of the Mediterranean diet. Apigenin is known to inhibit proliferation in different cancer cell lines by inducing G2/M arrest, but it is unclear whether this action is predominantly imposed on G2 or M phases. In this study, we demonstrate that apigenin arrests prostate cancer cells at G2 phase by flow cytometric analysis of prostate cancer cells co-stained for phospho-Histone H3 and DNA. Concurrently, apigenin also reduces the mRNA and protein levels of the key regulators that govern G2-M transition. Further analysis using chromatin immunoprecipitation (ChIP) confirmed the diminished transcriptional activities of the genes coding for these regulators. Unravelling the inhibitory effect of apigenin on G2-M transition in cancer cells provides the mechanistic understanding of its action and supports the potential for apigenin as an anti-cancer agent. Graphical Abstract

Keywords